

Linda R Gowing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6761693/publications.pdf>

Version: 2024-02-01

50
papers

3,176
citations

257357

24
h-index

330025

37
g-index

52
all docs

52
docs citations

52
times ranked

4286
citing authors

#	ARTICLE	IF	CITATIONS
1	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia, 2021, 215, S3-S32.	0.8	34
2	Brief Intervention for Illicit Drug Use. , 2021, , 655-671.		0
3	Is Long-Term Benzodiazepine Use a Risk Factor for Cognitive Decline? Results of a Systematic Review. Journal of Addiction, 2020, 2020, 1-10.	0.9	22
4	Pharmacotherapies for cannabis dependence. The Cochrane Library, 2020, 2020, CD008940.	1.5	35
5	Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. Handbook of Experimental Pharmacology, 2019, 258, 355-372.	0.9	5
6	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018, 113, 1905-1926.	1.7	685
7	Supervised dosing with a long-acting opioid medication in the management of opioid dependence. The Cochrane Library, 2017, 4, CD011983.	1.5	36
8	Opioid antagonists with minimal sedation for opioid withdrawal. The Cochrane Library, 2017, 2017, CD002021.	1.5	35
9	Buprenorphine for managing opioid withdrawal. The Cochrane Library, 2017, 2017, CD002025.	1.5	66
10	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology. , 2016, , 649-659.		1
11	Alpha₂-adrenergic agonists for the management of opioid withdrawal. The Cochrane Library, 2016, 2016, CD002024.	1.5	122
12	Opioid agonist treatment for pharmaceutical opioid dependent people. The Cochrane Library, 2016, , CD011117.	1.5	148
13	Psychosocial interventions for cannabis use disorder. The Cochrane Library, 2016, , CD005336.	1.5	141
14	Identifying correctionsâ€”is there a better way?. Addiction, 2015, 110, 1207-1207.	1.7	0
15	Reply to Warnakulasuriya<i> et al</i>.. Addiction, 2015, 110, 1533-1534.	1.7	1
16	Global statistics on addictive behaviours: 2014 status report. Addiction, 2015, 110, 904-919.	1.7	311
17	Alpha₂-adrenergic agonists for the management of opioid withdrawal. , 2014, , CD002024.		44
18	A systematic review and metaâ€”analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review, 2014, 33, 115-128.	1.1	41

#	ARTICLE	IF	CITATIONS
19	Pharmacotherapies for cannabis dependence. The Cochrane Library, 2014, , CD008940.	1.5	94
20	Supplementary Thiamine is Still Important in Alcohol Dependence. Alcohol and Alcoholism, 2013, 48, 88-92.	0.9	26
21	Mitigating the risk of HIV infection with opioid substitution treatment. Bulletin of the World Health Organization, 2013, 91, 148-149.	1.5	36
22	The role of opioid substitution treatment in reducing HIV transmission. BMJ, The, 2012, 345, e6425-e6425.	3.0	5
23	Maintenance drugs to treat opioid dependence. BMJ, The, 2012, 344, e2823-e2823.	3.0	18
24	Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane Library, 2011, , CD004145.	1.5	197
25	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. The Cochrane Library, 2010, , CD002022.	1.5	41
26	Buprenorphine for the management of opioid withdrawal. , 2009, , CD002025.		124
27	Alpha2-adrenergic agonists for the management of opioid withdrawal. , 2009, , CD002024.		39
28	Opioid antagonists with minimal sedation for opioid withdrawal. , 2009, , CD002021.		27
29	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98
30	Opioid antagonists with minimal sedation for opioid withdrawal. , 2006, , CD002021.		9
31	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. , 2006, , CD002022.		10
32	The place of detoxification in treatment of opioid dependence. Current Opinion in Psychiatry, 2006, 19, 266-270.	3.1	27
33	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. Journal of General Internal Medicine, 2006, 21, 193-195.	1.3	83
34	Buprenorphine for the management of opioid withdrawal. , 2006, , CD002025.		55
35	BRIEF REPORT: Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. Journal of General Internal Medicine, 2006, 21, 193-195.	1.3	66
36	Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy, 2005, 16, 67-75.	1.6	55

#	ARTICLE	IF	CITATIONS
37	Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving. Evidence-Based Mental Health, 2004, 7, 54-54.	2.2	1
38	Heroin users in Australia: population trends. Drug and Alcohol Review, 2004, 23, 107-116.	1.1	35
39	Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug and Alcohol Review, 2004, 23, 203-211.	1.1	38
40	Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug and Alcohol Dependence, 2004, 73, 219-226.	1.6	78
41	Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, , CD002024.		18
42	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. Drug and Alcohol Review, 2003, 22, 425-431.	1.1	11
43	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and Alcohol Dependence, 2002, 68, 5-14.	1.6	41
44	Which substitution pharmacotherapy is most effective in treating opioid dependence?. Medical Journal of Australia, 2002, 176, 493-494.	0.8	0
45	Î± 2 -Adrenergic agonists in opioid withdrawal. Addiction, 2002, 97, 49-58.	1.7	63
46	The health effects of ecstasy: a literature review. Drug and Alcohol Review, 2002, 21, 53-63.	1.1	126
47	Systematic review processes and the management of opioid withdrawal. Australian and New Zealand Journal of Public Health, 2000, 24, 427-431.	0.8	5
48	The management of opioid withdrawal. Drug and Alcohol Review, 2000, 19, 309-318.	1.1	15
49	Therapeutic use of cannabis: clarifying the debate. Drug and Alcohol Review, 1998, 17, 445-452.	1.1	3
50	Mg ²⁺ adenosine triphosphatase from cell envelopes of free-living and bacteroid forms of Rhizobium lupini strain NZP2257. Archives of Biochemistry and Biophysics, 1984, 232, 337-347.	1.4	2